NCT03653039 (Tritube) is a NA clinical trial of Tritube in Oral Neoplasm, sponsored by Michael Seltz Kristensen.

Who is sponsoring NCT03653039?

NCT03653039 is sponsored by Michael Seltz Kristensen.

What drugs are being tested in NCT03653039?

Interventions in NCT03653039: Tritube, Standard enditracheal tube.

What condition does NCT03653039 study?

NCT03653039 studies Oral Neoplasm, Pharynx Cancer, Larynx Cancer.

Is NCT03653039 still recruiting?

NCT03653039 is currently completed. Last updated 29 February 2024.

Last reviewed 2024-02-29 · How we verify

NCT03653039: Tritube

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison Between a Standard Tube and the Ultra-thin Tritube for Intubation of the Trachea and for Maintaining Access to the Trachea After Anaesthesia, in Patients With an Expected Difficult Direct Laryngoscopy

Completed NA Last updated 29 February 2024

What this trial tests

NA trial testing Tritube in Oral Neoplasm in 48 participants. Completed in 14 February 2019.

Timeline

12 September 2018

Primary endpoint
14 February 2019

14 February 2019

Quick facts

Lead sponsor	Michael Seltz Kristensen
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	48
Start date	12 September 2018
Primary completion	14 February 2019
Estimated completion	14 February 2019
Sites	1 location across Denmark

Drugs / interventions tested

Tritube
Standard enditracheal tube

Conditions studied

Oral Neoplasm — all drugs for Oral Neoplasm →
Pharynx Cancer — all drugs for Pharynx Cancer →
Larynx Cancer — all drugs for Larynx Cancer →

Sponsor

Michael Seltz Kristensen

Who can join

18 and older, any sex, with Oral Neoplasm or Pharynx Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators compare the ease of intubation between a new ultra-thin endotracheal tube, "Tritube", and a standard endotracheal tube in patients with predictors of difficult laryngoscopy. Furthermore the investigators compare the acceptance of leaving the Tritube in trachea after end of anaesthesia, with the use of a tube exchange catheter.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Oral Neoplasm

Currently open trials in the same condition.

NCT06662929 — Arabic PRO Measures for Head and Neck Cancer Radiotherapy. · recruiting
NCT04622462 — Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment · recruiting
NCT00542373 — Widefield Fluorescence and Reflectance Imaging Systems and Oral Tissue Samples in Monitoring Participants at Risk for De · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03653039 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Michael Seltz Kristensen
Last refreshed: 29 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03653039.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing